Optimization of use of levodopa in Parkinson's disease: Role of levodopa-carbidopa-entacapone combination;Optimización del uso de la levodopa en la enfermedad de Parkinson: Papel de la combinación levodopa-carbidopa-entacapona

Neurologia

Volumn 20, Issue 4, 2005, Pages 180-188

  Castro, A ^a   Valldeoriola, F ^b   Linazasoro, G ^c   Rodriguez Oroz M C ^d   Stochi, F ^e   Marin, C ^b   Rodriguez M ^f   Vaamonde, J ^g   Jenner, P ^h   Alvarez L ⁱ   Pavon N ⁱ   Macias R ⁱ   Luquin M R ^d   Hernandez B ^j   Grandas, F ^k   Gimenez Roldan S ^k   Tolosa, E S ^b   Obeso, José A ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL QUIRÓN   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSIDAD DE LA LAGUNA   (Spain)

^g Ciudad Sanitaria   (Spain)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^j S A   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

Continuous dopaminergic stimulation; Homocysteine; Motor complications; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; ENTACAPONE; HOMOCYSTEINE; LEVODOPA; OXIDOPAMINE;

ANIMAL CELL; CELL STRAIN; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MIXTURE; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; REVIEW; SYSTEMATIC REVIEW;

EID: 20444366197     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Obeso JA, Rodriguez-Oroz MC, Ghana P, Lera G, Rodríguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55(11 Suppl. 4): S13-23.
2. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16.
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence o dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 study group. N Engl J Med 2000;342:1484-91.
4. Luquin MR, Laguna J, Obeso JA. Selective D-2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992;31:551-4.
5. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with current model. Ann Neurol 2000;47:S22-34.
6. Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Bedard PJ, et al. Molecular basis of L-dopa-induced dyskinesias. Ann Neurol 2000;47:S70-8.
7. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends in Neurosciences 2000;23:S109-15.
8. Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walters RR, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356-A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-9.
9. Morissette M, Goulet M, Soghomonian JJ, Blanchet PJ, Calon F, Bedard PJ, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U01356A in continuous or intermittent mode of administration: comparison with l-dopa therapy. Brain Res Mol Brain Res 1997;49:56-62.
10. Bibbiani F, Constantini L, Patel R, Chase T. Continuous apomorphine administration with novel EVA implants reduces the risk of motor complications compared to pulsatile apomorphine in L-dopa-naive MPTP-lesioned primates. Neurology 2002;60 (Suppl.): 330.
11. Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord 1997;12:285-92.
12. Spencer SE, Wooten GF. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 1984;34:1105-8.
13. De la Fuente-Fernández R, Lu J-Q, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
14. Lozano AM, Lang AE, Levy R, Hutchinson W, Dostrovsky J. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Ann Neurol 2000;47(Suppl. 1):S141-6
15. Obeso JA, Rodríguez-Oroz MC, Marin C, Alonso F, Zamarbide I, Lanciego JL, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62(Suppl 1):S17-30.
16. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of l-dopa on dyskinesia induction in drug-naive MPTP treated common marmosets: effect of dose, frequency of administration and brain exposure. Mov Disord 2003;18:487-95.
17. Marin CM. Origen de las complicaciones motoras. Neurología 2003;18(Suppl. 1):2-10.
18. Jenner P, Al-Bartghouthy G, Smith L, Kuoppamaki M, Jackson M, Rose S, et al. Initiation of entacapone with L-dopa further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson's disease. Neurology 2002; 58(Suppl. 3):374-5.
19. Marín C, Aguilar E, Bonastre M, Tolosa E, Obeso JA. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 2005;192: 184-93.
20. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003;9(Suppl. 2):S73-81.
21. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonucelli V, Damier P, et al. Levodopa treatment in Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005.
22. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neurons firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003;6:968-73.
23. Rodríguez M, Macías R. Fisiología del sistema dopaminérgico nigroestriatal: implicaciones en el tratamíento de la enfermedad de Parkinson. Neurología 2002;17(Suppl. 1):28-36.
24. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993;61: 1470-8.
25. Mena MA, Pardo B, Casarejos MJ, Fahn S, García de Yébenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
26. Spencer JP, Jenner A, Butler J, Aruoma OI, Dexter DT, Jenner P, et al. Evaluation of the pro-oxidant and antioxidant actions of L-dopa and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 1996;24:95-105.
27. Mena MA, Pardo B, Paino CL, de Yébenes JG. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 1993;4:438-40.
28. Lyras L, Zeng BY, McKenzie G, Pearce RK, Hallivell B, Jenner P. Chronic high dose L-dopa alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigroestriatal pathway in normal cynomologus monkeys. J Neural Transm 2002;109:53-67.
29. Allain P, Le Bouil A, Cordillet E, Le Quay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995;16:527-9.
30. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-7.
31. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001;308:54-6.
32. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60:1125-9.
33. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005;20:69-72.
34. Heider I, Lehmensiek V, Lenk T, Muller T, Storch A. Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. J Neural Transm 2004(Suppl.);68:1-13.
35. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003;2:425-8.
36. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1553-661.
37. Whone A, Watts R, Stoessl J, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
38. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-8.
39. Fahn S. Parkinson's study group. Levodopa and the progression of Parkinson's disease. New Engl J Med 2004;351:2498-508.
40. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51:1309-14.
41. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
42. Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071-9.
43. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002; 105:245-55.
44. Myllyla W, Kultalahti ER, Haapaniemi H, Leinonen M, FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60.
45. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003;10:137-46.
46. th Congress of the European Federation of Neurological Societies (EFNS), 2003, Helsinki, Finland.
47. Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates. Mov Disord 2005;20:306-14.
48. Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61:1563-8.